- Lonza and Stipple Bio have entered a multi-target licensing agreement to support the development of precision oncology antibody-drug conjugate (ADC) therapies.
- The agreement provides Stipple Bio with access to Lonza’s ADC technology platform, including GlycoConnect®, HydraSpace®, and toxSYN® technologies, to support programs such as STP-100.
Lonza and Stipple Bio have announced a multi-target licensing agreement focused on the development of next-generation precision oncology antibody-drug conjugate (ADC) therapies. The collaboration combines Stipple Bio’s epitope discovery capabilities with Lonza’s ADC technology platform to support the development of targeted cancer treatments.
Under the agreement, Stipple Bio will gain target-specific access to Lonza’s ADC technologies to advance potential first-in-class and best-in-class ADC candidates, including its lead program, STP-100. Stipple Bio’s Pointillist Platform is designed to identify tumor-specific cell surface epitopes that may enable the development of therapies with improved precision and reduced off-target effects.
The licensing agreement includes access to Lonza’s GlycoConnect® antibody conjugation technology, HydraSpace® polar spacer technology, and toxSYN® linker payload platform. Lonza stated that it will manufacture components associated with its proprietary technologies, while Stipple Bio will be responsible for research, development, manufacturing, and commercialization of resulting ADC products.
“We value the opportunity to work with Stipple Bio to support their innovative epitope discovery approach with our advanced ADC technologies. By combining their science with Lonza’s established bioconjugation platforms and efficient, scalable manufacturing capabilities, we aim to help Stipple Bio progress more precise and effective ADC programs with confidence and speed.”
Jan Vertommen, Head of Commercial Development, Advanced Synthesis at Lonza
Financial terms of the agreement include upfront payments to Lonza as well as potential clinical, regulatory, and commercial milestone payments and royalties on net sales of products developed under the collaboration. The companies said the partnership is intended to support the advancement of precision oncology therapies through the integration of targeted epitope discovery and ADC technology platforms.
